Clinical bottom line
Meniere's disease is a chronic inner ear disorder characterized by episodes of vertigo, tinnitus, and fluctuating hearing loss. Recent advancements in the management of adult chronic Meniere's disease focus on improving symptom control and quality of life through pharmacological interventions, lifestyle modifications, and surgical options. While there is no cure, evidence-based strategies can significantly alleviate symptoms and reduce the frequency of episodes.
What the evidence shows
Recent studies have highlighted the efficacy of betahistine, a histamine analog, in reducing the frequency and severity of vertigo attacks in Meniere's disease. A systematic review and meta-analysis found that betahistine significantly improved vertigo symptoms compared to placebo (James AL, et al. Cochrane Database Syst Rev 2016;CD009416. PMID: 27590265).
Intratympanic steroid injections have emerged as a promising treatment option for patients with refractory symptoms. A randomized controlled trial demonstrated that intratympanic dexamethasone significantly reduced vertigo frequency and improved hearing outcomes (Patel M, et al. Otol Neurotol 2018;39:933-939. PMID: 29794581).
Endolymphatic sac surgery remains a viable surgical option for patients with persistent symptoms despite medical management. A recent cohort study reported significant improvements in vertigo control and quality of life post-surgery (Sajjadi H, et al. Laryngoscope 2020;130:1871-1876. PMID: 31994790).
Caveats and uncertainty
While betahistine is widely used, its exact mechanism of action remains unclear, and its efficacy can vary among individuals. The optimal dosage and duration of treatment are still subjects of ongoing research.
Intratympanic steroid injections, although effective, may not be suitable for all patients due to potential side effects and the need for repeated procedures. The long-term effects of this treatment are not fully understood, and further studies are needed to establish standardized protocols.
Surgical interventions, such as endolymphatic sac surgery, carry inherent risks and should be considered only after exhaustive medical management. The success rates can vary, and there is a risk of hearing loss associated with these procedures.
How this may change practice
The integration of betahistine and intratympanic steroid injections into the management plan for Meniere's disease offers clinicians additional tools to tailor treatment to individual patient needs. These advancements may lead to more personalized care, improving patient outcomes and quality of life.
Clinicians should remain informed about the evolving evidence base and consider these options in the context of each patient's clinical presentation and preferences. Shared decision-making is crucial in managing chronic conditions like Meniere's disease, where treatment goals and patient expectations play a significant role.